Skip to main content
NCBI home page
Pilot and Feasibility Studies logoLink to Pilot and Feasibility Studies
. 2020 May 18;6:67. doi: 10.1186/s40814-020-00614-0

Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome

Kimberly Legault 1,✉, Mark Blostein 2, Marc Carrier 3, Susan Kahn 2, Sam Schulman 1, Sudeep Shivakumar 4, Cynthia Wu 5, Mark A Crowther 1
PMCID: PMC7236369  PMID: 32477586

Correction to: Pilot Feasibility Stud 6, 52 (2020)

https://doi.org/10.1186/s40814-020-00594-1

Following publication of the original article [1], the authors opted to correct the last name of co-author Susan Kahn from Khan to Kahn.

Reference

  • 1.Legault K, Blostein M, Carrier M, et al. A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. Pilot Feasibility Stud. 2020;6:52. doi: 10.1186/s40814-020-00594-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Pilot and Feasibility Studies are provided here courtesy of BMC

RESOURCES